Sun Pharmaceutical Industries Acquires Concert Pharmaceuticals

Eli Lilly Acquires Centessa Pharmaceuticals

March 31, 2026

Biotechnology

Eli Lilly and Company entered into a definitive agreement to acquire clinical-stage biopharma Centessa Pharmaceuticals plc for $38.00 per share in cash, plus a non-transferrable contingent value right (CVR) that could bring total consideration to up to $47.00 per share. The deal is structured as a scheme of arrangement under the laws of England and Wales and was expected to close in Q3 2026, subject to shareholder and regulatory approvals and court sanction.

Sun Pharma Acquires Checkpoint Therapeutics

May 30, 2025

Biotechnology

Sun Pharmaceutical Industries Limited has completed the acquisition of Checkpoint Therapeutics, Inc., acquiring all outstanding shares for $4.10 per share in cash plus a contingent value right. The deal gives Sun Pharma ownership of UNLOXCYT (cosibelimab-ipdl), the FDA-approved anti-PD-L1 therapy for advanced cutaneous squamous cell carcinoma, and expands its oncology/onco-derm product portfolio.

Jazz Pharmaceuticals Acquires Chimerix for About $935 Million

March 5, 2025

Pharmaceuticals

Jazz Pharmaceuticals plc has entered into a definitive agreement to acquire Chimerix in an all-cash transaction valued at approximately $935 million (about $8.55 per share). The deal is expected to close in the second quarter of 2025, pending customary closing conditions, including tender of shares in a tender offer.

Concentra Biosciences (Tang Capital) to Acquire Theseus Pharmaceuticals

December 22, 2023

Biotechnology

Concentra Biosciences, a vehicle controlled by Tang Capital Partners, has entered into a definitive merger agreement to acquire clinical-stage biotech Theseus Pharmaceuticals for $3.90–$4.05 per share in cash plus a contingent value right tied to future program licensing/disposition proceeds. The transaction will be effected by a tender offer and is expected to close in February 2024, subject to customary conditions and the availability of required cash at closing.

Pfizer Acquires Arena Pharmaceuticals

December 13, 2021

Pharmaceuticals

Pfizer Inc. agreed to acquire clinical-stage Arena Pharmaceuticals for $100 per share in an all-cash transaction valued at approximately $6.7 billion, creating a wholly owned subsidiary. The acquisition brings Arena's development-stage portfolio — including etrasimod and cardiovascular assets — into Pfizer's Inflammation & Immunology pipeline to accelerate clinical development and expand therapeutic capabilities.

MorphoSys Acquires Constellation Pharmaceuticals for $1.7B

June 2, 2021

Biotechnology

MorphoSys AG has agreed to acquire Constellation Pharmaceuticals for $34.00 per share in cash, valuing the transaction at approximately $1.7 billion. The deal strengthens MorphoSys' hematology-oncology pipeline by adding Constellation's mid- to late-stage candidates (pelabresib/CPI-0610 and CPI-0209) and is supported by a strategic funding partnership with Royalty Pharma that provides significant upfront and milestone funding.